(Q38036773)

27 August 2017

title

Individualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician (English)

1 reference

27 August 2017

1 reference

Nancy J V Bohannon

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

27 August 2017

published in

Postgraduate Medicine

1 reference

27 August 2017

volume

124

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

95-108

1 reference

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Efficacy of metformin in the treatment of NIDDM. Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Activation of imidazoline I-2B receptor by metformin to increase glucose uptake in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Liraglutide as additional treatment for type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

The role of adjunctive exenatide therapy in pediatric type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

DPP-4 inhibitors and lipids: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Mechanism of action of sulphonylureas with special reference to the extrapancreatic effect: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

TCF7L2: the biggest story in diabetes genetics since HLA?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

TCF7L2 polymorphisms modulate proinsulin levels and beta-cell function in a British Europid population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Standards of medical care in diabetes--2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Is type 2 diabetes a different disease in obese and nonobese patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Intact proinsulin and beta-cell function in lean and obese subjects with and without type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Body mass index is the most important determining factor for the degree of insulin resistance in non-obese type 2 diabetic patients in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effect of short-term low-intensity exercise on insulin sensitivity, insulin secretion, and glucose and lipid metabolism in non-obese Japanese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Use of metformin in the setting of mild-to-moderate renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Medication taking and diabetes: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

A systematic review of adherence with medications for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Impact of fixed-dose combination drugs on adherence to prescription medications

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with establis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

21 January 2018

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Variants of transcription factor 7-like 2 (TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention Study and are associated with impaired glucose regulation and impaired insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2012.07.2572

21 January 2018

Identifiers

DOI

10.3810/PGM.2012.07.2572

1 reference

27 August 2017

1 reference